Thursday, November 19, 2026

NVIDIA BioNeMo Platform Lands Partnerships with Lilly, Thermo Fisher for Drug Discovery AI

NVIDIA's BioNeMo platform is driving coordinated AI infrastructure expansion in drug discovery through partnerships with pharmaceutical giants Eli Lilly and Thermo Fisher Scientific, alongside biotech firms Terray, Apheris, and TetraScience. Multiple concurrent product launches signal rapid ecosystem maturation around lab-in-the-loop AI workflows, marking a shift from experimentation to production-scale deployment in biopharma R&D.

This article was written by AI. Built from the source documents listed below. How we work

NVIDIA BioNeMo Platform Lands Partnerships with Lilly, Thermo Fisher for Drug Discovery AI
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

NVIDIA's BioNeMo platform has secured partnerships with Eli Lilly and Thermo Fisher Scientific to accelerate AI-driven drug discovery infrastructure.1 The collaborations extend to biotech innovators including Terray, Apheris, and TetraScience, focusing on foundation model development for pharmaceutical research.1

The BioNeMo platform orchestrates AI workflows that connect laboratory automation with machine learning models. Pharmaceutical companies are using the system to run iterative experiments where AI predictions guide physical lab work, creating feedback loops that refine molecular predictions.1

Several biotech companies have launched products on the platform. Natera, Basecamp Research's EDEN system, Owkin's OwkinZero, Edison's Kosmos, and Boltz Lab have released tools within the ecosystem.1 These launches indicate companies are moving beyond pilot projects to production deployment.

Eli Lilly's participation signals major pharmaceutical validation for the platform. Thermo Fisher's involvement brings laboratory equipment integration, connecting physical instrumentation to AI modeling systems. This hardware-software bridge enables automated experimental design where models propose tests and lab robots execute them.

Terray specializes in small molecule discovery, Apheris provides federated learning infrastructure for sensitive health data, and TetraScience focuses on lab data harmonization. Their combined capabilities address key bottlenecks: data quality, privacy constraints, and experimental throughput.

The lab-in-the-loop approach differs from pure computational drug discovery. AI models generate hypotheses about molecular properties, lab systems test predictions, and results train updated models. This cycle compresses discovery timelines by eliminating manual handoffs between computational and experimental teams.

NVIDIA positions BioNeMo as infrastructure rather than end-user software. The platform provides pre-trained models for protein structure, molecular properties, and biological sequences. Partners customize these foundations for specific therapeutic areas or screening workflows.

The pharmaceutical industry has historically struggled to operationalize AI research. Academic breakthroughs often fail to integrate with regulated manufacturing and clinical pipelines. BioNeMo's partnerships with established pharma and equipment vendors suggest the platform addresses integration challenges that stalled previous attempts.

Multiple concurrent product launches within months indicate ecosystem momentum. When infrastructure platforms reach critical mass, development accelerates as each new tool increases value for others. The BioNeMo ecosystem appears to have crossed this threshold in early 2026.

Source documents

Via News is a conduit. We point to the source documents behind this report: we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· January 12, 2026
    NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Built from 1 source document, dated 12 Jan 2026
  2. Published 29 Mar 2026 · Last updated 19 Nov 2026
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›

In this story

Via News Editorial Team

The Via News Editorial Team writes analysis and news from the Via News source-traceability system, under the editorial responsibility of L. Miguel Salvado, Editor. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. Articles generated with AI say so under the byline, as the EU AI Act requires.